

RESEARCH

Open Access



Cell-therapy for Parkinson's disease: a systematic review and meta-analysis

Fang Wang^{1†}, Zhengwu Sun^{2†}, Daoyong Peng^{1†}, Shikha Gianchandani³, Weidong Le⁴, Johannes Boltze³ and Shen Li^{5,6*} 

Abstract

Background Cell-based strategies focusing on replacement or protection of dopaminergic neurons have been considered as a potential approach to treat Parkinson's disease (PD) for decades. However, despite promising preclinical results, clinical trials on cell-therapy for PD reported mixed outcomes and a thorough synthesis of these findings is lacking. We performed a systematic review and meta-analysis to evaluate cell-therapy for PD patients.

Methods We systematically identified all clinical trials investigating cell- or tissue-based therapies for PD published before July 2023. Out of those, studies reporting transplantation of homogenous cells (containing one cell type) were included in meta-analysis. The mean difference or standardized mean difference in quantitative neurological scale scores before and after cell-therapy was analyzed to evaluate treatment effects.

Results The systematic literature search revealed 106 articles. Eleven studies reporting data from 11 independent trials (210 patients) were eligible for meta-analysis. Disease severity and motor function evaluation indicated beneficial effects of homogenous cell-therapy in the 'off' state at 3-, 6-, 12-, or 24-month follow-ups, and for motor function even after 36 months. Most of the patients were levodopa responders (61.6–100% in different follow-ups). Cell-therapy was also effective in improving the daily living activities in the 'off' state of PD patients. Cells from diverse sources were used and multiple transplantation modes were applied. Autografts did not improve functional outcomes, while allografts exhibited beneficial effects. Encouragingly, both transplantation into basal ganglia and to areas outside the basal ganglia were effective to reduce disease severity. Some trials reported adverse events potentially related to the surgical procedure. One confirmed and four possible cases of graft-induced dyskinesia were reported in two trials included in this meta-analysis.

Conclusions This meta-analysis provides preliminary evidence for the beneficial effects of homogenous cell-therapy for PD, potentially to the levodopa responders. Allogeneic cells were superior to autologous cells, and the effective transplantation sites are not limited to the basal ganglia.

PROSPERO registration number: CRD42022369760

Keywords Parkinson's disease, Cell-therapy, Homogenous cell, Transplantation, Meta-analysis

[†]Fang Wang, Zhengwu Sun, Daoyong Peng contributed equally to this study.

*Correspondence:

Shen Li

lishen@mail.ccmu.edu.cn

Full list of author information is available at the end of the article



Introduction

Parkinson's disease (PD) is the second most common neurodegenerative disease, and no curative therapy is currently available [1]. Thus, alternative solutions are urgently needed. PD has long been considered to be among the most promising target diseases for cell replacement therapy due to the specific loss of dopaminergic neurons in the substantia nigra [2], and cell-based therapies for PD has been explored clinically during the past decades. Initial studies mostly focused on transplantation of tissues such as embryonic mesencephalic tissue, adrenal medulla tissue, carotid body tissue, and sympathetic ganglion tissue. A meta-analysis on tissue transplantation demonstrated improved functional outcome [3]. However, tissue transplantation has several shortcomings including severe graft-induced dyskinesia (GID), substantial outcome heterogeneity, unsurmountable difficulties in quality control, immunogenicity, and ethical restrictions. Therefore, researchers gradually switched to transplantation of homogenous cells (defined as cell populations containing only one cell type that was extracted, isolated, expanded, and characterized). These comprise neural progenitor cells, fetal stem cells, bone marrow mesenchymal stem cells, retinal pigment epithelial cells, or induced pluripotent stem cells. With the advances in regenerative medicine, engineered cells are being tested as well. Lately, implantation of autologous, induced pluripotent stem cell-derived midbrain dopaminergic progenitor cells was reported [4], which may help to overcome ethical concerns if used properly. Although homogeneous cell transplantation is translationally promising, mixed results were reported from individual trials and no meta-analysis of those results has been conducted so far. A meta-analysis is therefore necessary to provide an overall assessment of the safety and efficacy of cell-therapy approaches in PD. In this study, we systematically reviewed all clinical trials on tissue or cell transplantation for PD and performed a meta-analysis for homogenous cells in treatment of PD.

Methods

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [5].

Search strategy

We systematically identified all clinical trials investigating cell-therapies for PD indexed in PubMed, Embase, Web of Science, and Cochrane databases before July 2023. The search terms were: (*Parkinson disease OR Parkinson's disease OR Parkinsonian disorders OR Parkinsonism OR Parkinsonisms OR Parkinson OR Parkinsons*) AND (*cell therapy OR cell therapeutics OR cell treatment OR cell*

treatments OR transplantation OR implantation), filtering for clinical trials. Only reports in English language were included.

FW and ZWS (review authors) screened studies for initial inclusion based on titles and abstracts. Full text screening for eligibility was performed if an initial decision could not be made. In case FW and ZWS could not reach a consensus, SL was consulted, followed by discussion and joint consensus in all cases. We also screened related reviews, together with reference lists of included publications, to identify other relevant articles [2, 6–9].

Inclusion and exclusion criteria for the systematic review

The inclusion criteria were: (1) recruited patients were diagnosed with idiopathic PD; (2) cell or tissue transplantation; (3) randomized controlled trials (RCTs), open-label studies, cohort studies, case reports, prospective studies, or retrospective studies.

Exclusion criteria were: (1) trials focusing on secondary PD or Parkinsonism-plus syndrome; (2) transplantation of more than one tissue type; (3) reviews and book chapters.

Additional inclusion and exclusion criteria for the meta-analysis

The studies included in the systematic review were further screened for the meta-analysis with the following inclusion criteria: (1) transplantation with homogenous cell populations (containing only one type of cells); (2) using objective methods to evaluate treatment responses such as imaging, biochemical indicators or quantitative scales, including Unified Parkinson Disease Rating Scale (UPDRS), or its part II/III (UPDRSII/UPDRSIII), Hoehn and Yahr (H&Y) Staging Scale, Beck Depression Inventory (BDI), Beck Anxiety Inventory, Mini-mental State Examination (MMSE), Parkinson's Disease Quality of Life Questionnaire, or Schwab and England Scale; (3) quantitative data available before and after cell-therapy.

Exclusion criteria were: (1) missing or incomplete reporting of efficacy endpoints or sample size; (2) transplantation of mixed or uncharacterized cell populations; (3) case reports. The study selection process is presented in Fig. 1a.

Data extraction

Data regarding study population, intervention, and outcome were extracted into a standardized form from texts and graphs in each study by the review authors. When only graphic representation was available, values of mean and standard deviation (SD) or standard error (SE) were estimated from high-resolution digital graphs using GetData Graph Digitizer v2.20. Study information including cell source, grafting location, cell dose,

sample size, patient age, disease duration, follow-up duration, primary and secondary endpoints, baseline (before transplantation) data, the clinical outcome information, as well as adverse events were collected. Adverse events were defined as an anticipated or unanticipated untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) whether or not related to cell transplantation. Neurological function before and after cell transplantation was compared for individual patients to evaluate treatment effects (self-comparison). For RCTs, baseline and outcome data were collected from the treatment groups. SE was converted to SD only when SE was reported.

Outcomes of interest were quantitative neurological scale scores in the 'on' or 'off' state. The 'off' state was defined as a period in which the patients withdrew anti-parkinsonian medication for 12 h [10]. The 'on' state was at the time of the patients' peak response to antiparkinsonian medication [10].

Risk of bias assessment

FW and ZWS independently assessed the risk of bias at the study level of included RCTs and non-RCTs in accordance with the Cochrane Collaboration Guidelines [11]. The risk of bias was assessed as 'low', 'moderate', 'high' or 'incomplete reporting' across the following domains: randomization; allocation concealment; blinding of therapists (intervention supervisors); blinding of patients; blinding of outcome assessors; handling of incomplete data (use of intention-to-treat analysis); selective reporting; and multivariate adjustment for potential confounders. Discrepancies in the risk of bias assessment were resolved by discussion among review authors and SL.

Statistical analysis

The mean difference (MD) or standardized mean difference (SMD) in quantitative neurological scale scores before and after cell-therapy was analyzed to evaluate the treatment effects. Forest plots were created to depict both the pooled MD or SMD along with their 95% confidence intervals (CI). The statistical significance of the pooled effect size of all studies was judged by a Z-test. A P value < 0.05 was considered statistically significant.

We considered only trials that demonstrated clinical homogeneity to be appropriate for meta-analysis. Potential heterogeneity between studies was initially explored through a visual exploration of the forest plots. A test for statistical heterogeneity (a consequence of clinical or methodological diversity, or both, among trials) was then performed using Cochran's Q-statistic test (P value < 0.1 indicating significance) and I^2 analysis using the following equation:

$$I^2 = [(Q - df)/Q] \times 100\%.$$

in which Q is the Chi^2 statistic and df is its degrees of freedom. This describes the percentage of variability in effect estimates that is due to heterogeneity rather than sampling error (chance). Values greater than 50% are considered to represent substantial heterogeneity. When values were $> 70\%$, we attempted to interpret the variation. If the value was less than 30%, we presented the overall estimate using a fixed-effect model. If there was evidence of heterogeneity ($I^2 > 30\%$) between trials, we used a random-effect model based on the DerSimonian and Laird method [12]. A leave-one-out sensitivity analysis was performed by iteratively removing one study at a time to confirm whether the findings were driven by any single study. Potential publication bias was evaluated using funnel plots. Review Manager 5.3 was used to complete all statistical calculations.

Results

Study characteristics and systematic review of the literature

Overview on retrieved records

The initial search returned 903 records, of which 136 were retrieved for full-text review (Fig. 1a). One hundred and six articles were included in the systematic review [4, 13–117]. Eighty-nine articles reported tissue transplantation or transplantation of mixed cell populations, including 66 articles using embryonic mesencephalic tissues (Additional file 9: Table S1) [13–78], 16 articles reporting adrenal medulla tissue transplantation (Additional file 10: Table S2) [79–94], two articles reporting carotid body tissue transplantation [95, 96], four sympathetic ganglion tissue transplantation articles [97–100], and one adipose-derived stromal vascular fraction cell transplantation (Fig. 1b) [101]. Seventeen publications

(See figure on next page.)

Fig. 1 **a** PRISMA flow diagram. **b** Pie chart of the total number of publications on different types of tissue or cell transplantation between 1982 and 2021. **c** Numbers of publications on different types of tissue or cell transplantation in each decade. The numbers of articles on embryonic mesencephalic tissue transplantation published in 1982–1991, 1992–2001, 2002–2011, 2012–2021 are 8, 39, 16 and 3, respectively. Articles reporting adrenal medulla transplantation are 12, 4, 0, and 0. Articles reporting sympathetic ganglion transplantation are 0, 3, 1 and 0. Articles on transplantation of other tissue are 0, 0, 2 and 1. Transplantation of homogenous cell populations are 0, 0, 6 and 11, respectively




Fig. 1 (See legend on previous page.)

reported transplantation of homogenous cell populations [4, 102–117]. One hundred and four articles explored treatment efficacy, 63 articles reported safety, 92 articles investigated motor symptoms, and 18 articles examined non-motor symptoms. There were 84 articles using allotransplantation, 5 articles on xenotransplantation, and 17 articles on autotransplantation.

Changes in predominantly used cell material over time

Predominantly used cell sources for PD treatment changed over time (Fig. 1c). Adrenal medulla tissue transplantation was the most widely studied approach before 1991 (n=12) and was observed until 2001, but not thereafter. Embryonic mesencephalic tissue transplantation was investigated across all four decades and with most reports published in 1992–2001 (n=39), gradually decreasing after 2002. Autonomic ganglion tissue transplantation was performed in a few studies between 1992–2011 (n=3+1). Other tissues were investigated by one or two studies only. Treatment with homogenous cell populations became a research focus after 2002 and the most frequently used treatment strategy in the recent decade.

Transplantation of allogenic tissues

A total of 297 patients receiving embryonic mesencephalic tissue transplantation were included in this review. These studies investigated different outcomes using a broad range of methods including structural imaging, functional imaging, electrophysiology, biochemical indicators, functional outcome measurements by various scales, and pathological studies by autopsy. Some studies indicated that transplants partially replaced dopaminergic neurons following intra-striatal transplantation, and improved symptoms [41, 46, 51, 75]. Double-blind, sham-controlled clinical trials did not confirm statistically significant benefits from fetal mesencephalic tissue transplantation but revealed adverse events such as GID [20, 23].

Transplantation of autologous tissues

The usage of autologous cells is not limited by ethical considerations and avoids severe immune reactions. Autologous cell or tissue transplantation to supply DA was therefore investigated as a potential treatment for PD patients. These autologous DA-secreting cells or tissues included adrenal medulla and carotid body tissues, and sympathetic neurons. In the pioneering work performed by Backlund and collaborators [94], autologous adrenal medulla cells were implanted into the striatum of four patients to provide a local catecholamine source, but the beneficial effects were minimal. In the following 10 years, clinical studies on adrenal medulla transplantation of 148

PD patients yielded similar results and several autopsies demonstrated that the transplanted adrenal cells did not survive in the host brain [118].

The carotid body contains neural crest-derived dopaminergic glomus cells that are similar to the chromaffin cells of the adrenal medulla. These cells function as arterial oxygen sensors and release large amounts of dopamine in response to hypoxia. In addition, glial cell line-derived neurotrophic factor (GDNF) secreted from the carotid body might exert neuroprotective effects for these dopaminergic glomus cells as well as nigrostriatal neurons [119]. A pilot study and a phase I-II blinded clinical study were performed using bilateral intra-striatal transplantation of autologous carotid body cells in patients with advanced-stage PD (n=6 and 13, respectively) [95, 96]. Functional improvement was seen in five and ten patients, respectively, and no patients developed GID.

Some studies investigated the potential of autologous sympathetic neurons since the ganglion contains not only norepinephrinergic but also dopaminergic cells. Long-term clinical evaluation revealed that unilateral intrastriatal implantation of autologous cervical sympathetic ganglion tissue results in a significant improvement of PD symptoms, particularly akinesia and gait disturbance, and a reduction in the patient's daily levodopa intake [99]. Following the development of video-guided endoscopic thoracic surgery, it became possible to safely excise three or more ganglia from the thoracic sympathetic trunk in a minimally invasive manner. This option may augment the amount of available tissue, thereby increasing the number of implantation sites. One study endoscopically excised and re-transplanted thoracic sympathetic ganglia in a total of five PD patients [98]. These autografts were found to improve the patients' performance by reducing the time spent in the off phase. However, there have been no further clinical studies using these cells.

One study investigated intranasal administration of autologous adipose-derived stromal vascular fraction cells in two patients [101]. Both patients exhibited improvements in motor and non-motor functions one and five years after transplantation. There is, however, no clear understanding of the underlying mechanism, and any reported results should be confirmed in future studies.

Meta-analysis on studies investigating transplantation of homogenous cell populations

Seventeen publications reported transplantation of homogenous cell populations and 11 were eligible for this meta-analysis [102–112]. Two publications were reporting results from one study [112, 113]. Two publications were case reports [4, 117]. Three publications did not

Table 1 Characteristics of the studies and subjects included in the meta-analysis

| Study | Patient | | Intervention | | | | Follow-up (months) | Outcome | Study type and origin |
|--------------------------|---------|-------------|-------------------------|---|---|---|--------------------|--------------------------|---|
| | N/male | Age (years) | Disease duration (year) | Cell type | Cell count | Graft location | | | |
| Schiess 2021 [102] | 20/11 | 66.4 ± 7.0 | 5.5 ± 1.8 | Allogeneic bone marrow mesenchymal stem cells | 1, 3, 6, or 10 × 10 ⁶ /kg | Intravenous infusion | 3, 6, 12 | (1), (3)-(5), (9), (11) | Prospective, single-center, USA |
| Venkataramana 2012 [103] | 8/7 | 54.6 ± 10.0 | 8.3 ± 3.8 | Allogeneic bone marrow mesenchymal stem cells | 2 × 10 ⁶ /kg | Bilateral subventricular zone | 12 | (1), (8), (11) | Prospective, single-center, India |
| Boika 2020 [104] | 12/7 | 49.8 ± 12.4 | 5.7 ± 5.5 | Autologous bone marrow mesenchymal stem cells | 0.5–2 × 10 ⁶ /kg 5–12.6 × 10 ⁶ /kg | Intravenous infusion Intravenous + intranasal | 1, 3 | (3), (6), (9) | Prospective, single-center, Belarus |
| Storch 2012 [105] | 7/5 | 60.6 ± 12.9 | 10.3 ± 2.9 | Autologous bone marrow mesenchymal stem cells | 2 × 10 ⁶ | Intrathecal injection + intravenous infusion | 1–15 | (1), (4), (5) | Retrospective, multi-center, German and Italy |
| Brazzini 2010 [106] | 53/37 | 61.8 ± 10.7 | 9.1 ± 5.4 | Autologous bone marrow stem cells | NP | Superselective intraarterial (posterior region of the circle of Willis) | 1–18 | (1), (4)-(6), (11) | Retrospective, single-center, USA |
| Madrazo 2019 [107] | 7/5 | 54.3 ± 10.9 | 7.7 ± 5.5 | Allogeneic human neural progenitor cells | 2 × 10 ⁶ | Bilateral dorsal putamina | 12, 24, 48 | (1)-(7), (11)-(13) | Prospective, single-center, Mexico |
| Lige 2016 [108] | 21/15 | 57.3 ± 9.1 | NP | Allogeneic human neural precursor cells | 3 × 10 ⁷ | Unilateral striatum | 7–57 | (1)-(9), (11) | Prospective, single-center, China |
| Sinelnyk 2015 [109] | 32/22 | 47.2 ± 6.7 | NP | Allogeneic fetal stem cells | 5.46 × 10 ⁶ | Vein and anterior abdominal | 6, 12 | (5), (6), (8) | Prospective, single-center, USA |
| Yin 2012 [110] | 12/5 | 66.3 ± 11.9 | 6.4 | Allogeneic human retinal pigment epithelial cells | 1 × 10 ⁶ | Unilateral postcommissural putamen | 3, 6, 12, 24, 36 | (1)-(5), (11), (14) | Prospective, single-center, China |
| Gross 2011 [111] | 35/22 | 56.4 ± 7.5 | NP | Allogeneic human retinal pigment epithelial cells | 6.5 × 10 ⁵ | Bilateral postcommissural putamen | 12, 24, 36, 48 | (2), (3), (5), (9), (11) | RCT, multi-center, USA |
| Stover 2005 [112] | 6/3 | 52.2 | 10.2 | Allogeneic human retinal pigment epithelial cells | 3.25 × 10 ⁵ | Unilateral postcommissural putamen | 3, 6, 12, 18, 24 | (1)-(3), (9), (10) | Prospective, single-center, USA |

NP not provided, RCT randomized controlled trial, N the number of patients

(1) = Unified PD Rating Scale (UPDRS); (2) = UPDRS II; (3) = UPDRS III; (4) = Hoehn and Yahr (H&Y) staging; (5) = Schwab and England scale; (6) = Beck Depression Inventory; (7) = Beck Anxiety Inventory; (8) = Mini-mental State Examination (MMSE); (9) = PDQ-39; (10) = the time in 'off' state; (11) = Magnetic Resonance (MR) Imaging; (12) = PET Molecular Imaging (¹⁸F-FDOPA); (13) = PET Molecular Imaging (vesicular monoamine transporter 2, VMAT2); (14) = PET Molecular Imaging (¹¹C-β-CFT)

report the quantitative data necessary for this analysis. Attempts to contact the corresponding authors failed and these studies were therefore excluded [114–116]. An overview of research protocols and subject characteristics is shown in Table 1.

Risk of bias analysis

The risk of bias assessment is summarized in Table 2. Ten studies were non-RCTs that did not describe the processes of random sequence generation or allocation concealment in sufficient detail. They were considered

Table 2 Internal validity of included studies

| Study | Prospective design | Multicenter enrollment | Selection bias | Performance bias | Attrition bias | Detection bias | Multivariate adjustment for potential confounders |
|--------------------------|--------------------|------------------------|----------------|------------------|----------------|----------------|---|
| Schiess 2021 [102] | Yes | No | D | B | A | D | Probably adequate |
| Venkataramana 2012 [103] | Yes | No | D | B | C | A | Probably adequate |
| Boika 2020 [104] | Yes | No | D | B | A | D | Probably adequate |
| Storch 2012 [105] | No | Yes | D | D | C | D | Not reported |
| Brazzini 2010 [106] | No | No | D | B | A | C | Not reported |
| Madrazo 2019 [107] | Yes | No | D | B | A | D | Probably adequate |
| Lige 2016 [108] | Yes | No | D | B | A | D | Not reported |
| Sinelnyk 2015 [109] | Yes | No | D | B | A | D | Probably adequate |
| Yin 2012 [110] | Yes | No | D | B | A | A | Probably adequate |
| Gross 2011 [111] | Yes | Yes | A | A | A | A | Probably adequate |
| Stover 2005 [112] | Yes | No | D | B | A | D | Probably adequate |

Risk of bias is expressed as A=low, B=moderate, C=high, or D=incomplete reporting

as incomplete regarding the risk of bias reporting when evaluating selection bias. In most of the studies included for meta-analysis, it was neither practical nor possible to blind the participants or therapists. This was considered a low risk of performance bias for the therapists, but a moderate risk for the participants. Those studies reporting a dropout or loss of follow-up rate higher than 20% were believed to have a high level of attrition bias. Studies were rated as high-risk for detection bias when neither employing intention-to-treat principles in the data analysis nor describing dropouts, nor blinding evaluators to treatment. All other bias assessment domains shown in Table 2 were considered to have a low risk of bias.

Effects of homogeneous cell populations in PD Disease course and disability

UPDRS (monitoring the disease course and the degree of disability) or UPDRSIII (evaluation of motor function) scores were examined in 'on' or 'off' state at various post-intervention time points. These follow-ups were different across the nine studies reporting those and varied from 1 to 57 months (last follow-up, Table 1). A total of 210 patients were investigated in the included trials. Meta-analysis was performed on the last follow-up across studies, and at intermediate follow-up time points (3-, 6-, 12-, 24-, and ≥ 36 -month follow-ups) when those were reported by the respective studies.

The meta-analysis revealed overall better post- versus pre-treatment function although considerable heterogeneity was evident (Additional file 1: Fig. S1). There was a beneficial effect of homogenous cell-therapy on UPDRS scores in the 'off' state at the last follow-up and at 3-, 6-, 12- and 24-month follow-ups, but not at the ≥ 36 -month follow-up (Fig. 2). However, the latter was only reported

by two studies (Fig. 2). UPDRS scores showed relative homogeneity in the 'off' state at 3-, 6-month and ≥ 36 -month follow-up analysis (Fig. 2). Moreover, cell treatment improved UPDRS scores in the 'on' state at the 12-month follow-up, but not at the last follow-up, or at 24-, ≥ 36 -month follow-ups (Additional file 2: Fig. S2). There was no profound heterogeneity among 12-, 24-, ≥ 36 -month follow-ups, but at the last follow-up. This might be explained by different transplantation paradigms. For instance, Brazzini et al. infused bone marrow stem cells intraarterially [106], while other studies administered cells directly into the basal ganglia. Removing the study of Brazzini et al. (leaving-one-out analysis) reduced the heterogeneity to 16%, but the overall result remained unchanged (95% CI -8.95 to 19.03). When analyzing the H&Y scale, we revealed the overall positive effects of cell-therapy at the last assessed timepoints in 'on' or 'off' state (Additional file 3: Fig. S3). However, there was no change in the levodopa equivalent dose of antiparkinsonian medications after 12 months ($P=0.56$, $I^2=0\%$, 95% CI -103.43 to 191.50).


Motor symptoms

Seven studies measured the effects of homogenous cell-therapy on motor symptoms [102, 104, 107, 108, 110–112]. A random-effect model was used to compare the pre- versus post-treatment UPDRSIII scores in the 'off' state at the study last follow-up. The meta-analysis yielded a better outcome after cell treatment, but the heterogeneity was high (Fig. 3). This might be related to the design of the study by Lige et al. who did not use a fixed observation time. Analyzing the UPDRSIII scores after cell treatment in the 'off' state at 3-, 6-, 12-, 24-, and ≥ 36 -month follow-ups revealed positive effects

a. The last follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|-------|-----------|----------------------|-------|-----------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Lige 2016 | 80.71 | 15.48 | 21 | 72.76 | 13.31 | 21 | 26.1% | 7.95 [-0.78, 16.68] |
| Madrazo 2019 | 47.3 | 14.3 | 7 | 40.3 | 12.2 | 7 | 18.2% | 7.00 [-6.92, 20.92] |
| Schiess 2021 | 50.4 | 8 | 20 | 31.8 | 5.3 | 20 | 33.3% | 18.60 [14.39, 22.81] |
| Stover 2005 | 118 | 14.1 | 6 | 75.2 | 24.5 | 6 | 10.0% | 42.80 [20.18, 65.42] |
| Venkataramana 2012 | 90.1 | 39.3 | 7 | 59.5 | 41.7 | 6 | 3.3% | 30.60 [-13.68, 74.88] |
| Yin 2012 | 82.9 | 28.7 | 12 | 64 | 32.1 | 12 | 9.0% | 18.90 [-5.46, 43.26] |
| Total (95% CI) | | | 73 | | | 72 | 100.0% | 16.56 [8.12, 24.99] |


Heterogeneity: Tau² = 51.01; Chi² = 12.03, df = 5 (P = 0.03); I² = 58%
 Test for overall effect: Z = 3.85 (P = 0.0001)



b. 3-month follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Fixed, 95% CI |
|-----------------------|---------------------|------|-----------|----------------------|------|-----------|---------------|--------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Schiess 2021 | 50.4 | 8 | 20 | 29.2 | 7.6 | 20 | 92.0% | 21.20 [16.36, 26.04] |
| Stover 2005 | 118 | 14.1 | 6 | 82.4 | 25 | 6 | 4.1% | 35.60 [12.63, 58.57] |
| Yin 2012 | 82.9 | 28.7 | 12 | 55.3 | 29.7 | 12 | 3.9% | 27.60 [4.23, 50.97] |
| Total (95% CI) | | | 38 | | | 38 | 100.0% | 22.04 [17.40, 26.68] |


Heterogeneity: Chi² = 1.67, df = 2 (P = 0.43); I² = 0%
 Test for overall effect: Z = 9.31 (P < 0.00001)



c. 6-month follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-----------|----------------------|------|-----------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Schiess 2021 | 50.4 | 8 | 20 | 29.5 | 6 | 20 | 57.8% | 20.90 [16.52, 25.28] |
| Stover 2005 | 118 | 14.1 | 6 | 79.5 | 18.8 | 6 | 23.8% | 38.50 [19.70, 57.30] |
| Yin 2012 | 82.9 | 28.7 | 12 | 51.1 | 28.3 | 12 | 18.4% | 31.80 [9.00, 54.60] |
| Total (95% CI) | | | 38 | | | 38 | 100.0% | 27.09 [15.47, 38.70] |


Heterogeneity: Tau² = 55.72; Chi² = 3.90, df = 2 (P = 0.14); I² = 49%
 Test for overall effect: Z = 4.57 (P < 0.00001)



d. 12-month follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-----------|----------------------|------|-----------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Madrazo 2019 | 47.3 | 14.3 | 7 | 30.4 | 11.8 | 7 | 24.2% | 16.90 [3.17, 30.63] |
| Schiess 2021 | 50.4 | 8 | 20 | 31.8 | 5.3 | 20 | 31.8% | 18.60 [14.39, 22.81] |
| Stover 2005 | 118 | 14.1 | 6 | 67.4 | 18.4 | 6 | 19.9% | 50.60 [32.05, 69.15] |
| Venkataramana 2012 | 90.1 | 39.3 | 7 | 59.5 | 41.7 | 6 | 7.0% | 30.60 [-13.68, 74.88] |
| Yin 2012 | 82.9 | 28.7 | 12 | 43.7 | 25.9 | 12 | 17.2% | 39.20 [17.33, 61.07] |
| Total (95% CI) | | | 52 | | | 51 | 100.0% | 28.93 [15.77, 42.09] |


Heterogeneity: Tau² = 137.39; Chi² = 14.17, df = 4 (P = 0.007); I² = 72%
 Test for overall effect: Z = 4.31 (P < 0.0001)



e. 24-month follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-----------|----------------------|------|-----------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Madrazo 2019 | 47.3 | 14.3 | 7 | 36.6 | 13.4 | 7 | 39.4% | 10.70 [-3.82, 25.22] |
| Stover 2005 | 118 | 14.1 | 6 | 75.2 | 24.5 | 6 | 30.4% | 42.80 [20.18, 65.42] |
| Yin 2012 | 82.9 | 28.7 | 12 | 52 | 28.6 | 12 | 30.1% | 30.90 [7.98, 53.82] |
| Total (95% CI) | | | 25 | | | 25 | 100.0% | 26.56 [6.50, 46.62] |

Heterogeneity: Tau² = 210.89; Chi² = 6.15, df = 2 (P = 0.05); I² = 67%
 Test for overall effect: Z = 2.59 (P = 0.009)



f. ≥36-month follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Fixed, 95% CI |
|-----------------------|---------------------|------|-----------|----------------------|------|-----------|---------------|--------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Madrazo 2019 | 47.3 | 14.3 | 7 | 40.3 | 12.2 | 7 | 75.4% | 7.00 [-6.92, 20.92] |
| Yin 2012 | 82.9 | 28.7 | 12 | 64 | 32.1 | 12 | 24.6% | 18.90 [-5.46, 43.26] |
| Total (95% CI) | | | 19 | | | 19 | 100.0% | 9.93 [-2.16, 22.02] |

Heterogeneity: Chi² = 0.69, df = 1 (P = 0.41); I² = 0%
 Test for overall effect: Z = 1.61 (P = 0.11)






Fig. 2 UPDRS scores pre- versus post-transplantation in the 'off' state at last follow-up, or 3-, 6-, 12-, 24-, and ≥ 36-month follow-ups. The number of studies included in each analysis are 6, 3, 3, 5, 3, and 2, respectively. If the I² value is less than 30%, a fixed-effect model is used. If the I² value is greater than 30%, a random-effect model is used. The sizes of the squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI, confidence interval (represented by the lines)


a. The last follow-up




b. 3-month follow-up




c. 6-month follow-up



d. 12-month follow-up



e. 24-month follow up



f. ≥36-month follow-up




Fig. 3 UPDRSIII score pre- versus post-transplantation in the ‘off’ state at last follow-up, or 3-, 6-, 12-, 24-, and ≥ 36-month follow-ups. The number of studies included in each analysis are 7, 4, 3, 5, 4, and 3, respectively. If the I² value is less than 30%, a fixed-effect model is used. If the I² value is greater than 30%, a random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI, confidence interval (represented by the lines)

(Fig. 3, Additional file 4: Fig. S4). Analyzing UPDRSIII scores in the ‘on’ state revealed beneficial effects of cell treatment at the 6- and 24-month follow-ups compared to baseline status, but neither at the last follow-up nor at 3- or 12-month follow-ups (Fig. 4). The inter-study heterogeneity was low at the last follow-up and at 3-, 6-, and 24-month follow-ups (Fig. 4). The 12-month follow-ups showed a high heterogeneity. This can be explained by the study of Gross et al. [111], as its RCT design was different from the other three open-labeled

pilot studies. Leaving this study out reduced the I^2 value to 0%.


Non-motor symptom-depression

Three studies examined the effects of homogenous cell-therapy on non-motor symptoms [106, 107, 109]. The Beck Depression Inventory (BDI) was used to evaluate the degree of depression in patients but did not reveal significant differences after cell treatment. There was considerable heterogeneity between studies probably

a. The last follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Fixed, 95% CI |
|-----------------------|---------------------|------|-------|----------------------|------|-------|---------------|--------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Boika 2020 | 27.3 | 18.5 | 12 | 22.8 | 14.1 | 12 | 20.4% | 4.50 [-8.66, 17.66] |
| Madrazo 2019 | 11.6 | 9.8 | 7 | 14 | 12.4 | 7 | 25.7% | -2.40 [-14.11, 9.31] |
| Stover 2005 | 19.6 | 9.4 | 6 | 11.2 | 9.6 | 6 | 30.5% | 8.40 [-2.35, 19.15] |
| Yin 2012 | 37.4 | 17.4 | 12 | 27.9 | 13 | 12 | 23.4% | 9.50 [-2.79, 21.79] |
| Total (95% CI) | 37 | | | 37 | | | 100.0% | 5.08 [-0.86, 11.02] |


Heterogeneity: Chi² = 2.44, df = 3 (P = 0.49); I² = 0%
Test for overall effect: Z = 1.68 (P = 0.09)



b. 3-month follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Fixed, 95% CI |
|-----------------------|---------------------|------|-------|----------------------|------|-------|---------------|--------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Boika 2020 | 27.3 | 18.5 | 12 | 22.8 | 14.1 | 12 | 28.4% | 4.50 [-8.66, 17.66] |
| Stover 2005 | 19.6 | 9.4 | 6 | 14.3 | 9.4 | 6 | 43.4% | 5.30 [-5.34, 15.94] |
| Yin 2012 | 37.4 | 17.4 | 12 | 28.1 | 15.5 | 12 | 28.2% | 9.30 [-3.88, 22.48] |
| Total (95% CI) | 30 | | | 30 | | | 100.0% | 6.20 [-0.80, 13.21] |


Heterogeneity: Chi² = 0.30, df = 2 (P = 0.86); I² = 0%
Test for overall effect: Z = 1.73 (P = 0.08)



c. 6-month follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Fixed, 95% CI |
|-----------------------|---------------------|------|-------|----------------------|------|-------|---------------|--------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Stover 2005 | 19.6 | 9.4 | 6 | 13.1 | 9.2 | 6 | 56.9% | 6.50 [-4.02, 17.02] |
| Yin 2012 | 37.4 | 17.4 | 12 | 24.9 | 12.4 | 12 | 43.1% | 12.50 [0.41, 24.59] |
| Total (95% CI) | 18 | | | 18 | | | 100.0% | 9.09 [1.15, 17.02] |


Heterogeneity: Chi² = 0.54, df = 1 (P = 0.46); I² = 0%
Test for overall effect: Z = 2.24 (P = 0.02)



d. 12-month follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-------|----------------------|------|-------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Gross 2011 | 18.4 | 8.78 | 35 | 19.7 | 8.68 | 35 | 32.9% | -1.30 [-5.39, 2.79] |
| Madrazo 2019 | 11.6 | 9.8 | 7 | 5.7 | 3.6 | 7 | 25.8% | 5.90 [-1.83, 13.63] |
| Stover 2005 | 19.6 | 9.4 | 6 | 11.6 | 7.2 | 6 | 22.5% | 8.00 [-1.47, 17.47] |
| Yin 2012 | 37.4 | 17.4 | 12 | 21.6 | 10.9 | 12 | 18.8% | 15.80 [4.18, 27.42] |
| Total (95% CI) | 60 | | | 60 | | | 100.0% | 5.86 [-1.33, 13.05] |

Heterogeneity: Tau² = 36.52; Chi² = 10.38, df = 3 (P = 0.02); I² = 71%
Test for overall effect: Z = 1.60 (P = 0.11)



e. 24-month follow-up

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-------|----------------------|------|-------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Madrazo 2019 | 11.6 | 9.8 | 7 | 10.1 | 8.6 | 7 | 37.8% | 1.50 [-8.16, 11.16] |
| Stover 2005 | 19.6 | 9.4 | 6 | 11.2 | 9.5 | 6 | 33.1% | 8.40 [-2.29, 19.09] |
| Yin 2012 | 37.4 | 17.4 | 12 | 22.8 | 11.2 | 12 | 29.1% | 14.60 [2.89, 26.31] |
| Total (95% CI) | 25 | | | 25 | | | 100.0% | 7.59 [0.17, 15.01] |

Heterogeneity: Tau² = 13.58; Chi² = 2.92, df = 2 (P = 0.23); I² = 31%
Test for overall effect: Z = 2.01 (P = 0.04)





Fig. 4 UPDRSIII score pre- versus post-transplantation in the ‘on’ state at last follow-up, or 3-, 6-, 12-, 24-, and ≥ 36-month follow-ups. The number of studies included in each analysis are 4, 3, 2, 4, and 3, respectively. If the I^2 value is less than 30%, a fixed-effect model is used. If the I^2 value is greater than 30%, a random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI, confidence interval (represented by the lines)

a. 'Off' state

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Fixed, 95% CI |
|--|---------------------|------|-----------|----------------------|------|-----------|---------------|--------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Lige 2016 | 28.52 | 7.96 | 21 | 23.62 | 7.55 | 21 | 35.0% | 4.90 [0.21, 9.59] |
| Madrazo 2019 | 12.7 | 4.2 | 7 | 10.3 | 4.7 | 7 | 35.3% | 2.40 [-2.27, 7.07] |
| Stover 2005 | 24.2 | 4.5 | 6 | 16.7 | 7.2 | 6 | 16.7% | 7.50 [0.71, 14.29] |
| Yin 2012 | 26.3 | 10.1 | 12 | 18.4 | 9.11 | 12 | 13.0% | 7.90 [0.20, 15.60] |
| Total (95% CI) | | | 46 | | | 46 | 100.0% | 4.84 [2.07, 7.62] |
| Heterogeneity: Chi ² = 2.25, df = 3 (P = 0.52); I ² = 0% | | | | | | | | |
| Test for overall effect: Z = 3.42 (P = 0.0006) | | | | | | | | |



b. 'On' state

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---------------------|------|-----------|----------------------|------|-----------|---------------|--------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Madrazo 2019 | 7.7 | 4.4 | 7 | 8.9 | 5.7 | 7 | 39.8% | -1.20 [-6.53, 4.13] |
| Stover 2005 | 8.7 | 3.1 | 6 | 6.3 | 6 | 6 | 38.8% | 2.40 [-3.00, 7.80] |
| Yin 2012 | 17.3 | 9.51 | 12 | 11.4 | 8.66 | 12 | 21.4% | 5.90 [-1.38, 13.18] |
| Total (95% CI) | | | 25 | | | 25 | 100.0% | 1.72 [-1.65, 5.08] |
| Heterogeneity: Chi ² = 2.48, df = 2 (P = 0.29); I ² = 19% | | | | | | | | |
| Test for overall effect: Z = 1.00 (P = 0.32) | | | | | | | | |




Fig. 5 UPDRSII score pre- versus post-transplantation in the 'off' and 'on' states at the last follow-up. The number of studies included are 4 and 3, respectively. Fixed-effect models are used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI, confidence interval (represented by the lines)

resulting from diverse transplantation modes (using bilateral basal ganglia transplantation [107], combined intravenous and subcutaneous routes [109], and intra-arterial transplantation [106], respectively) (Additional file 5: Fig. S5).

Activities of daily living (ADL)

ADL were assessed using UPDRSII or the Schwab and England score. Four studies examined the UPDRSII scores in the 'off' state at the last follow-up [107, 108, 110, 112]. A fixed-effect model revealed a better outcome after homogenous cell-therapy. Three studies assessed UPDRSII scores in the 'on' state (all used allogeneic cells) but did not report treatment effects. There was no obvious heterogeneity (Fig. 5) [107, 110, 112].

Patients potentially benefited from cell-therapy

There was no study investigating whether the effects of cell-therapy are influenced by patient sex. All studies included had equivalent male/female ratio and an average disease course of more than 5 years. The average age was between 47.2 and 66.4 years. Six studies included in the meta-analysis clearly stated that the enrolled patients had positive responses to dopaminergic therapy [102, 104, 107, 110–112]. Five studies did not specify levodopa responsiveness. In the analyses of UPDRS scores in the 'off' state, the proportion of levodopa-responsive patients was 100%, 100%, 86.5%, 100% and 100% at 3-, 6-, 12-, 24-, and ≥36-month follow-ups and 61.6% at last follow up, respectively (Fig. 2). The fraction of levodopa-responsive patients was 76%, 100%, 100%, 100%, 100% at 3-, 6-, 12-, 24-, and ≥36-month follow-ups, and 81.4% at last follow-up, in the analyses of UPDRSIII scores in the 'off' state,


respectively (Fig. 3). The patients who were responsive to dopaminergic therapy showed functional improvements on UPDRS, UPDRSIII, and UPDRSII scores in the 'off' state at the last follow-up, but not in the 'on' state (Fig. 6).

Impact of cell immunogenicity and cell type on outcome


Eight studies used allogeneic, and three studies used autologous cells for transplantation. Allogeneic cells (neural progenitor cells, fetal stem cells, retinal pigment epithelial cells, and bone marrow mesenchymal stem cells) showed beneficial effects on UPDRS, UPDRSIII, and UPDRSII scores in the 'off' state at the last follow-up, but not in the 'on' state (Additional file 6: Fig. S6) [102, 103, 107, 108, 110–112]. There were considerable heterogeneities in the UPDRSIII score analyses in the 'off' state, which might be explained by one study not defining fixed observation time points (last follow-up ranged from 7–57 months)[108]. Removing this study reduced the I² value to 37% but did not change the overall result. When autografts (mesenchymal stem cells that cannot differentiate into neural cells) were used, no beneficial effect was observed on H&Y scores in 'off' or 'on' state (Additional file 7: Fig. S7) [105, 106]. Even though homogenous cell-therapy in general and allogeneic cells in particular showed positive effects on motor function in the 'off' state, autologous cell transplantation did not show such effects.

Several types of cells were transplanted including neural progenitor cells (n=2), fetal stem cells (n=1), bone marrow mesenchymal stem cells (n=4), other bone marrow stem cells (including exact cell type not specified, n=1), and retinal pigment epithelial cells (n=3). UPDRS or UPDRSIII assessments in the 'off' states at the


a. UPDRS in the state of "off"




b. UPDRSIII in the state of "off"




c. UPDRSII in the state of "off"



d. UPDRS in the state of "on"



e. UPDRSIII in the state of "on"



f. UPDRSII in the state of "on"





Fig. 6 UPDRS, UPDRSIII and UPDRSII scores pre- versus post-transplantation in the 'off' and 'on' states at the last follow-up with levodopa responders. The number of studies included are 4, 6, 3, 2, 5, and 3, respectively. If the I² value is less than 30%, a fixed-effect model is used. If the I² value is greater than 30%, a random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI, confidence interval (represented by the lines)

a. Retinal pigment epithelium cells-UPDRS in the state of 'off'

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-------|----------------------|------|-------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Stover 2005 | 118 | 14.1 | 6 | 75.2 | 24.5 | 6 | 51.9% | 42.80 [20.18, 65.42] |
| Yin 2012 | 82.9 | 28.7 | 12 | 64 | 32.1 | 12 | 48.1% | 18.90 [-5.46, 43.26] |
| Total (95% CI) | 18 | | | 18 | | | 100.0% | 31.30 [7.89, 54.70] |


Heterogeneity: Tau² = 141.76; Chi² = 1.99, df = 1 (P = 0.16); I² = 50%
 Test for overall effect: Z = 2.62 (P = 0.009)



b. Retinal pigment epithelium cells-UPDRSIII in the state of 'off'

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-------|----------------------|------|-------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Gross 2011 | 48.8 | 7.74 | 35 | 37.5 | 13.8 | 35 | 52.2% | 11.30 [6.06, 16.54] |
| Stover 2005 | 51.9 | 8.7 | 6 | 30.7 | 7.2 | 6 | 32.9% | 21.20 [12.16, 30.24] |
| Yin 2012 | 51.8 | 18.7 | 12 | 40.8 | 21.4 | 12 | 14.9% | 11.00 [-5.08, 27.08] |
| Total (95% CI) | 53 | | | 53 | | | 100.0% | 14.51 [7.58, 21.44] |


Heterogeneity: Tau² = 16.79; Chi² = 3.56, df = 2 (P = 0.17); I² = 44%
 Test for overall effect: Z = 4.10 (P < 0.0001)



c. Stem cells-UPDRS in the state of 'off'

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-------|----------------------|------|-------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Lige 2016 | 80.7 | 15.4 | 21 | 72.7 | 13.3 | 21 | 31.9% | 8.00 [-0.70, 16.70] |
| Madrazo 2019 | 47.3 | 14.3 | 7 | 40.3 | 12.2 | 7 | 20.0% | 7.00 [-6.92, 20.92] |
| Schiess 2021 | 50.4 | 8 | 20 | 31.8 | 5.3 | 20 | 45.1% | 18.60 [14.39, 22.81] |
| Venkataramana 2012 | 90.1 | 39.3 | 7 | 59.5 | 41.7 | 6 | 3.0% | 30.60 [-13.68, 74.88] |
| Total (95% CI) | 55 | | | 54 | | | 100.0% | 13.26 [5.30, 21.23] |

Heterogeneity: Tau² = 32.05; Chi² = 6.74, df = 3 (P = 0.08); I² = 55%
 Test for overall effect: Z = 3.26 (P = 0.001)



d. Stem cells-UPDRSIII in the state of 'off'

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-------|----------------------|------|-------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Boika 2020 | 41.2 | 15.8 | 12 | 32.5 | 15.7 | 12 | 15.9% | 8.70 [-3.90, 21.30] |
| Lige 2016 | 35.5 | 6.5 | 21 | 33.4 | 5.2 | 21 | 31.2% | 2.10 [-1.46, 5.66] |
| Madrazo 2019 | 27.9 | 9.5 | 7 | 23 | 8.1 | 7 | 21.1% | 4.90 [-4.35, 14.15] |
| Schiess 2021 | 33.8 | 6.1 | 20 | 21.3 | 3.5 | 20 | 31.8% | 12.50 [9.42, 15.58] |
| Total (95% CI) | 60 | | | 60 | | | 100.0% | 7.05 [0.16, 13.94] |

Heterogeneity: Tau² = 36.39; Chi² = 19.17, df = 3 (P = 0.0003); I² = 84%
 Test for overall effect: Z = 2.00 (P = 0.04)




Fig. 7 UPDRS and UPDRSIII scores pre- versus post-transplantation in the 'off' state at the last follow-ups after retinal pigment epithelium cell and stem/progenitor cell treatment. The number of studies included are 2, 3, 4, and 4, respectively. Random-effect models are used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI, confidence interval (represented by the lines)

last follow-up revealed better outcomes after retinal pigment epithelium cell and stem/progenitor cell treatment (Fig. 7). The heterogeneity was low in retinal pigment epithelial cell studies. However, the UPDRSIII analysis of stem/progenitor cell-therapy revealed high heterogeneity, potentially due to the study of Lige et al. not defining fixed observation time points [108]. Removing this study reduced the I² value to 21%.

Transplantation route


Among the 11 studies included in this meta-analysis, six studies performed intraparenchymal transplantation into the basal ganglia (Table 1) [103, 107, 108, 110–112]. Unilateral and bilateral intraparenchymal transplantation was performed in three studies each. One study investigated intravenous infusion of allogeneic bone marrow-derived mesenchymal stem cells

[102]. One study transplanted autologous mesenchymal stem cells through intravenous or tandem (intranasal + intravenous) injections [104]. One study combined intravenous and subcutaneous transplantation of fetal stem cells [109]. One study injected autologous bone marrow mesenchymal stem cells via intrathecal and intravenous injection [105]. One study infused bone marrow stem cells using a superselective intraarterial approach to the posterior region of the circle of Willis [106]. Basal ganglia transplantation resulted in beneficial effects on both UPDRS and UPDRSIII scores in 'off' state at the last follow-ups. Non-basal ganglia transplantation improved UPDRSIII scores. However, the I² value for UPDRSIII scores were high for transplantation into basal ganglia, which might again be explained by the study of Lige et al. (Fig. 8) [108].

a. Basal ganglia-UPDRS

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-----------|----------------------|------|-----------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Lige 2016 | 80.7 | 15.4 | 21 | 72.7 | 13.3 | 21 | 33.1% | 8.00 [-0.70, 16.70] |
| Madrazo 2019 | 47.3 | 14.3 | 7 | 40.3 | 12.2 | 7 | 26.6% | 7.00 [-6.92, 20.92] |
| Stover 2005 | 118 | 14.1 | 6 | 75.2 | 24.5 | 6 | 17.4% | 42.80 [20.18, 65.42] |
| Venkataramana 2012 | 90.1 | 39.3 | 7 | 59.5 | 41.7 | 6 | 6.8% | 30.60 [-13.68, 74.88] |
| Yin 2012 | 82.9 | 28.7 | 12 | 64 | 32.1 | 12 | 16.0% | 18.90 [-5.46, 43.26] |
| Total (95% CI) | | | 53 | | | 52 | 100.0% | 17.08 [4.41, 29.74] |


Heterogeneity: Tau² = 106.17; Chi² = 9.41, df = 4 (P = 0.05); I² = 58%
 Test for overall effect: Z = 2.64 (P = 0.008)



b. Basal ganglia-UPDRSIII

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Random, 95% CI |
|-----------------------|---------------------|------|-----------|----------------------|------|-----------|---------------|---------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Gross 2011 | 48.8 | 7.7 | 35 | 37.5 | 13.8 | 35 | 24.3% | 11.30 [6.06, 16.54] |
| Lige 2016 | 35.5 | 6.5 | 21 | 33.4 | 5.2 | 21 | 26.2% | 2.10 [-1.46, 5.66] |
| Madrazo 2019 | 27.9 | 9.5 | 7 | 23 | 8.1 | 7 | 18.9% | 4.90 [-4.35, 14.15] |
| Stover 2005 | 51.9 | 8.7 | 6 | 30.7 | 7.2 | 6 | 19.2% | 21.20 [12.16, 30.24] |
| Yin 2012 | 51.8 | 18.7 | 12 | 40.8 | 21.4 | 12 | 11.4% | 11.00 [-5.08, 27.08] |
| Total (95% CI) | | | 81 | | | 81 | 100.0% | 9.55 [2.49, 16.60] |

Heterogeneity: Tau² = 46.21; Chi² = 19.68, df = 4 (P = 0.0006); I² = 80%
 Test for overall effect: Z = 2.65 (P = 0.008)



c. Non-basal ganglia-UPDRSIII

| Study or Subgroup | Pre-transplantation | | | Post-transplantation | | | Weight | Mean Difference IV, Fixed, 95% CI |
|-----------------------|---------------------|------|-----------|----------------------|------|-----------|---------------|--------------------------------------|
| | Mean | SD | Total | Mean | SD | Total | | |
| Boika 2020 | 41.2 | 15.8 | 12 | 32.4 | 15.7 | 12 | 5.6% | 8.80 [-3.80, 21.40] |
| Schiess 2021 | 33.8 | 6.1 | 20 | 21.3 | 3.5 | 20 | 94.4% | 12.50 [9.42, 15.58] |
| Total (95% CI) | | | 32 | | | 32 | 100.0% | 12.29 [9.30, 15.29] |

Heterogeneity: Chi² = 0.31, df = 1 (P = 0.58); I² = 0%
 Test for overall effect: Z = 8.05 (P < 0.00001)




Fig. 8 UPDRS and UPDRSIII scores pre- versus post-transplantation in the ‘off’ state at the last follow-ups after basal ganglia and non-basal ganglia transplantation. The number of studies included are 5, 5, and 2, respectively. If the I² value is less than 30%, a fixed-effect model is used. If the I² value is greater than 30%, a random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI, confidence interval (represented by the lines)

Cell doses

The cell doses used for transplantation were between 1 and 10 × 10⁶/kg in the ten studies investigated. In one study, four doses (1, 3, 6, or 10 × 10⁶/kg) of allogeneic bone marrow-derived mesenchymal stem cells were administered intravenously to investigate a potential dose-dependent efficacy [102]. The results showed that all doses showed effects on motor symptoms in the ‘off’ state. However, the highest dose achieved the maximum absolute improvement at the 52 weeks follow-up and reduced the UPDRS motor and total scores in the ‘off’ state. Therefore, the included studies suggested that cell doses between one to ten million were all effective.

Imaging readouts

Seven included studies applied magnetic resonance (MR) imaging for outcome evaluation [102, 103, 106–108, 110, 111], among which four [107, 108, 110, 111] investigated safety endpoints including inflammatory responses, tumor formation, bleeding, and edema after cell transplantation. Three other studies [102, 103, 106] used MR spectroscopy, MR perfusion, and MR tractography for efficacy evaluation. In one study,

MR spectroscopy revealed a significant increase of the mean n-acetylaspartate/creatinine ratio in basal ganglia after transplantation [106]. One study showed MR perfusion increased overall from baseline to 24 weeks post infusion in all basal ganglia structures [102]. Another study reported a statistically non-significant trend of improvement in fractional anisotropic (FA) values of MR tractography in the genu and the cerebral peduncles steadily over a period of 12 months after transplantation [103]. Two studies employed positron emission tomography (PET) imaging to evaluate the efficacy [107, 110]. The radiopharmaceuticals included FDOPA, DTBZ, and ¹¹C-β-CFT. FDOPA and DTBZ imaging showed a statistically non-significant trend toward enhanced midbrain dopaminergic activity at one year after grafting in one study [107]. The other study showed a statistically non-significant trend towards increased dopamine release in ¹¹C-β-CFT PET imaging during the first 6 months after transplantation [110]. These studies suggested that cell-therapy partially replaced dopaminergic neurons. Due to the heterogeneity in imaging methodology, the limited number of studies and overall small sample sizes, however, prevented a meaningful meta-analysis of the imaging readouts regarding efficacy.

Table 3 Adverse events and immunosuppression

| Study | Sample size | Adverse events | | | | Immunosuppression |
|--------------------------|-------------|----------------|------------------|-------------------------------|--|----------------------------|
| | | Tumor | Immune rejection | GID | Others | |
| Schiess 2021 [102] | 20 | No | No | 4 patients (possibly related) | Phlebitis, hematoma, hypertension, nausea, headache, lymphocytosis | Not performed |
| Venkataramana 2012 [103] | 8 | No | No | No | No | Not performed |
| Boika 2020 [104] | 12 | NP | NP | NP | NP | Not performed |
| Storch 2012 [105] | 7 | No | No | NP | NP | NP |
| Brazzini 2010 [106] | 53 | No | No | No | No | Not performed |
| Madrazo 2019 [107] | 7 | No | No | No | No | Cyclosporine A for 40 days |
| Lige 2016 [108] | 21 | No | No | No | No | Not performed |
| Sinelnyk 2015 [109] | 32 | No | No | No | No | Not performed |
| Yin 2012 [110] | 12 | No | No | No | No | Not performed |
| Gross 2011 [111] | 35 | No | No | 1 patient | Disturbance in attention, hallucination | Not performed |
| Stover 2005 [112] | 6 | No | No | No | Hallucination | Not performed |

GID graft-induced dyskinesia, NP not provided

Adverse events of homogenous cell transplantation

The reports for adverse events of homogenous cell-therapy for PD are listed in Table 3. No tumor formation or severe immune rejections were observed. Two trials reported GID [102, 111]. There were other adverse events including surgical injury and complications, such as phlebitis and hematoma. Psychonosema was noted such as hallucination or disturbance in attention.

Sensitivity analysis

Sensitivity analyses were performed to evaluate the robustness of the estimated pooled effect size for UPDRS, UPDRSIII, UPDRSII scores and non-motor symptoms. The pooled effect was stable for UPDRSIII and UPDRSII in the 'off' state and non-motor symptoms, indicating that these results were not driven by any single study. However, when either the study by Brazzini et al. [106] or the one by Lige et al. [108] was removed, statistical significance was lost for the pooled effect size of homogenous cell-therapy on H&Y scores in the 'on' or 'off' state at the last follow-up. On the contrary, when the study of Madrazo et al. [107] was removed, cell-therapy became beneficial for UPDRS and UPDRSIII scores in the 'on' state at the last follow-up. Removing the study of Gross et al. [111] also resulted in the detection of a cell treatment effect on UPDRSIII scores in the 'on' state at the 12-month follow-up.

Publication bias

Funnel plots were plotted for the meta-analysis including more than 5 studies (Additional file 8: Fig. S8). These plots were symmetrical and evenly distributed, and few

effects fell outside the 99% CI, suggesting that the present meta-analyses were not substantially affected by publication bias.

Discussion

Tissue transplantation

Intracerebral grafting of fetal mesencephalic tissue, which is rich in dopaminergic neuroblasts, was first reported in 1979, ameliorating the symptoms of experimental PD rats [120, 121]. Thereafter, about 400 PD patients were grafted with human fetal mesencephalic tissue in the 1980s–1990s. Fetal tissue grafts have survived over two decades in some patients despite ongoing PD pathology [122]. In addition, several trials showed engraftment of fetal tissue with wide outgrowth and robust innervation of the host striatum by donor-derived DA neurons [54, 56, 58, 66, 123, 124]. However, due to GID, fetal tissue transplantation was abandoned. The overall discouraging results may be partly related to differences between studies in cell sources, preparation, and transplantation paradigms [23, 124]. In addition, multiple fetal donors (typically 3–5) were pooled to obtain sufficient numbers of cells for one patient. This may contribute to the heterogeneity of outcomes and may indicate a lack of material for widespread clinical usage. Ethical arguments also limit fetal tissue transplantation. Therefore, transplantation of human fetal mesencephalic tissue is very unlikely to be developed into a routine treatment for PD patients.

Autologous adrenal medulla and carotid body tissues, and sympathetic neurons were explored as PD treatments because these can either secrete DA or exert neurotrophic effects, but their precise therapeutic mechanism

is uncertain [95–100]. Tissue transplantation was less investigated in the recent decade. Lately, the concept experienced a renaissance due to advances in regenerative medicine and tissue engineering, using optimized grafting and defined immunosuppression protocols [2]. Successful *in-vitro* differentiation of embryonic stem cells [125–127] or induced pluripotent stem cells [4] towards a midbrain dopaminergic fate may allow the development of cell-therapies for PD while avoiding many practical and ethical concerns regarding tissue transplantation, although there are still many challenges in translating *in-vitro* success to *in-vivo* applications, and potential ethical concerns surrounding embryonic stem cells usage. What remains is the need for cell transplants that can not only functionally integrate but survive in the host brain over long periods.

Therapeutic effects of homogenous cell-therapy on PD

To the best of our knowledge, this is the most comprehensive meta-analysis of clinical trials on cell treatments for PD to date. Both cell origin and the site of cell transplantation varied considerably across the studies. Most transplantations (6 out of 11) were performed into basal ganglia uni- or bilaterally. Follow-up time ranged from 1 to 57 months. The key finding from our meta-analysis is that homogenous cell transplantation significantly improves clinical outcomes in PD patients regarding overall disease severity, motor symptoms, and ADL in the 'off' state.

The main outcome measurement in our meta-analysis was based on the UPDRS score which is believed to be less susceptible to observer bias than other scores [128]. Therefore, it is less likely that the clinical improvements observed can be solely attributed to observer bias. Our findings suggest that the investigated cell treatments have a robust effect on the 'off' state at the 3-, 6-, 12-, 24-, and even ≥ 36 -month follow-ups for motor symptoms. There was indication that the magnitude and duration of functional improvement induced by dopaminergic grafts depend on patient selection, with good preoperative response to L-dopa predicting good response to the graft [129, 130]. In this meta-analysis most of the patients included were responsive to dopaminergic therapy, and those patients may also be responsive to cell-therapy. Patients with DA neuron loss restricted to the caudate and putamen are more likely to experience long-term benefits from dopaminergic grafts placed in these areas [14, 25, 129, 130]. In contrast, long-lasting beneficial outcomes in PD patients with more widespread DA neuron loss are less likely [14].

Most of the trials in our meta-analysis included PD patients with a good response to L-dopa. This may explain why UPDRS and UPDRSIII at the 'on' state did

not improve much, as the combination of both treatments would require a significant additional effect that may not be detected with the overall limited numbers of patients investigated. No difference between neurological function pre- and post-transplantation was found in the UPDRS score in the 'off' state at ≥ 36 months. Graft function may be compromised by delayed immune reactions, previously characterized by microglial infiltration into the graft [23]. However, UPDRSIII scores in the 'off' state at ≥ 36 months provide preliminary evidence that the cell graft was still functional, but more rigorous RCTs and long-term follow-up studies, especially those ≥ 36 months are needed to confirm this. Those should include tailored assessment of graft functionality, for instance by sophisticated brain imaging.

Only few clinical trials investigating homogenous cell-therapy for PD have focused on the management of non-motor symptoms: four articles investigated cognition [102, 103, 107, 109], four articles reported depression [104, 106, 107, 109], one studied anxiety article [107], and two examined sleep-disorder [104, 109]. Although a significant decrease of non-motor symptoms and depression, as well as an improvement in objective parameters of sleep quality, were reported in PD patients after cell treatment in single studies [109], we could not confirm these findings in our meta-analysis. Several factors could have contributed to this. Firstly, non-motor symptoms may originate from degeneration outside the striatum or in non-dopaminergic systems that may be difficult to target with cell-therapy. Secondly, the cell grafts investigated may simply lack the ability to counter these symptoms. Third and most importantly, the relatively high inter-study heterogeneity regarding cell type and source, transplantation site, and other aspects may just have 'masked' minor yet clinically meaningful effects on these endpoints. Therefore, it is crucial to scrutinize non-motor symptoms in future investigations. In summary, the overall positive impact on ADL parameters observed in our meta-analysis may primarily originate from motor symptom improvements. However, overall results should be interpreted with caution as the overall number of available and included studies is relatively low.

Effects of different cell sources and transplantation modes on efficacy

Most of the included studies ($n=8$) transplanted allogeneic cells for PD patients and exhibited robust beneficial effects on UPDRS, UPDRSIII, and UPDRSII scores in the 'off' state. However, autografts were ineffective in symptoms examined by H&Y score changes in 'off' or 'on' states as there were not sufficient autograft transplantation studies to be combined to evaluate the UPDRS changes. The three articles evaluating autografts all used

bone marrow mesenchymal stem cells [104–106], which may not differentiate into neural tissue. However, they may exert beneficial immunomodulatory and neuroprotective effects. Moreover, six out of the eight articles evaluating allogeneic cells used neural progenitor cells, fetal stem cells, or retinal pigment epithelial cells. Those might be able to differentiate into neuronal cells. Thus, allogeneic cells and autologous cells likely have different mechanisms of action. Therefore, it is rational to speculate that the overall positive effects of homogenous cell-therapy for PD patients in our meta-analysis were mainly due to allogeneic cell transplantation studies and that allogeneic cells may be a better option for PD treatment, particularly, retinal pigment epithelium cell and stem/progenitor cell. Besides, allogeneic cells have some logistical advantages as they can be obtained and prepared in advance and under standardized conditions. They might also be advantageous in inherited PD. However, when using allogeneic cells, the immunological barrier represents a formidable obstacle for the transplanted cells to survive and execute therapeutic effects relying on differentiation and functional integration. Fortunately, with the development of modern immunosuppressants, graft survival and side effects have been greatly improved [131].

Unexpectedly, we observed that transplantation outside basal ganglia was also effective to improve motor function in PD patients. In these two studies, the intravenously infused bone marrow mesenchymal stem cells were likely to improve PD symptoms through immunomodulatory mechanisms, such as decreasing inflammatory cytokine production, reducing microglial activation and α -synuclein oligomerization [102, 104]. This observation may be clinically relevant because such transplantation, in particular systemic cell delivery, may not only be safer and easier to perform, but also less expensive and time-consuming. However, this result is based on a limited number of studies and thus will require confirmation, and the likelihood of immunological consequences is far greater after systematic cell delivery.

Other factors as, for instance, gender, age, and disease courses of the patients may also act as confounding factors. However, due to the lack of available raw data, we were unable to analyze their impact on reported functional outcomes after cell-therapy.

Adverse events of homogenous cell-therapy

No tumor formation or severe immune rejections were reported in the included studies, but one trial reported a case of GID, and another trial reported four cases of possibly GID. Off-state GID was a relatively frequent adverse event after human fetal mesencephalic tissue transplantation. The interpretation of this phenomenon is difficult. Modeling studies suggest that some form of

L-DOPA-induced postsynaptic supersensitivity, established before transplantation, may play a role [132, 133]. Moreover, small, intracerebral transplants may be more prone to cause GID by forming ‘hot-spots’ of DA release, while the surrounding striatum remains supersensitive [133, 134]. Finally, a potential role of excessive serotonin innervation has been discussed [8, 135, 136]. Fetal mesencephalic tissue often used for transplantation also contains serotonergic neurons, and studies on 6-hydroxydopamine-induced PD models suggested that these could exacerbate dyskinesia induced by L-DOPA [135]. Clinical research suggested that a non-optimal ratio between serotonergic and dopaminergic neurons (or their progenitors) in grafts causes GID [136–138]. The relatively low incidence of GID in the studies included in our meta-analysis may be related to patient selection, improvement of surgical methods, and higher homogeneity of transplanted cells. Other adverse events such as surgical complications (phlebitis and hematoma) and psychoses were generally rare. However, two included studies did not provide comprehensive adverse effect reports, which limit the understanding of potential risks associated with the intervention. Due to the inconsistency in reporting of adverse events, we were also unable to compare the safety profiles of different interventions. A thorough and robust safety analysis is imperative for future clinical trials.

Quality of evidence and limitations

Despite the generally encouraging results of our meta-analysis, it is important to keep in mind that most of the included studies were open-label, single-center trials, with outcome data not reported or inadequately described in some studies. Moreover, insufficient information on disease duration in some studies limits the understanding of how the disease stage could affect the treatment outcomes and impact the quality and reliability of the analysis. Although blinding of the participants and therapists was not possible, outcome assessors can be blinded. Nevertheless, a relatively large proportion of studies ($n=5$, 41.7%) did not report blinding of outcome assessors. Thus, the results may still contain observer bias.

Another major limitation is that our meta-analysis cannot provide a thorough perspective on how cell-therapies for PD may be improved further. The main reasons are the small number of studies and the overall heterogeneity of cell and tissue types being used. While there is an overall positive effect of cell-based treatments, any kind of optimal approach cannot be identified from this relatively small dataset. Moreover, we can only speculate why systemic cell administration was effective or why overall best effects were obtained with allogeneic cells, and both findings may appear

counter-intuitive. A combination of thorough preclinical and clinical research is required to solve these questions. Mechanistic investigations in relevant animal models should identify the most effective cell types and transplantation paradigms while multicenter, large-scale, and double-blinded RCTs are needed to verify the encouraging yet preliminary results of our meta-analysis. Alternative solutions, such as pharmacological therapy and deep brain stimulation, should also be considered in conjunction with cell-based therapies.

Conclusion

According to this meta-analysis, cell therapy was effective for improving disease severity and motor symptoms while also improving ADL in the 'off' state of PD patients, especially in levodopa responders. Allogeneic cells exerted beneficial effects on these parameters, but autografts did not. Transplantation of cells to areas outside the basal ganglia, including system transplantation of cells, was able to induce therapeutic benefits. Some trials reported adverse events potentially related to the surgical procedure. One confirmed and four possible cases of GID were reported in two trials included in meta-analysis. Therefore, our results suggest modest yet clinically meaningful cell therapy effects in patients with PD although definitive evidence must be provided by future double-blinded large-scale RCTs. These should also monitor the long-term safety of cell-based interventions for PD while the optimal cell population and route of transplantation need to be defined. Cell-therapies in PD are not a stand-alone treatment but must always be considered in combination with established therapies.

Abbreviations

| | |
|-------|---|
| ADL | Activities of daily living |
| BDI | Beck Depression Inventory |
| CI | Confidence interval |
| DA | Dopamine |
| FA | Fractional anisotropic |
| GDNF | Glial cell line-derived neurotrophic factor |
| GID | Graft-induced dyskinesia |
| H&Y | Hoehn and Yahr Staging Scale |
| MD | Mean difference |
| MMSE | Mini-mental State Examination |
| MR | Magnetic Resonance |
| PD | Parkinson's disease |
| PET | Positron emission tomography |
| RCT | Randomized controlled trial |
| SD | Standard deviation |
| SE | Standard error |
| SMD | Standardized mean difference |
| UPDRS | Unified Parkinson Disease Rating Scale |

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12967-023-04484-x>.

Additional file 1: Fig. S1. UPDRS or UPDRSIII scores pre- versus post-transplantation in 'on' or 'off' state at the last follow-up. Nine studies are included. Random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI = confidence interval (represented by the lines).

Additional file 2: Fig. S2. UPDRS score pre- versus post-transplantation in the 'on' state at the last follow-up, or at 12-, 24-, and ≥ 36 -month follow-ups. The number of studies included are 4, 3, 2, and 2, respectively. If the I^2 value is less than 30%, a fixed-effect model is used. If the I^2 value is greater than 30%, a random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI = confidence interval (represented by the lines).

Additional file 3: Fig. S3. H-Y score pre- versus post-transplantation in the 'on' or 'off' states at the last follow-up. Four studies are included. Random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI = confidence interval (represented by the lines).

Additional file 4: Fig. S4. UPDRSIII score pre- versus post-transplantation in the 'off' state at 48-month follow-up. Two studies are included. Fixed-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI = confidence interval (represented by the lines).

Additional file 5: Fig. S5. Beck Depression inventory score pre- versus post-transplantation in the 'on' or 'off' states at the last follow-up. Three studies are included. Random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI = confidence interval (represented by the lines).

Additional file 6: Fig. S6. UPDRS, UPDRSIII and UPDRSII scores pre- versus post-transplantation in the 'off' and 'on' states at the last follow-ups after allogeneic cell treatment. The number of studies included are 6, 6, 4, 3, 3, and 3, respectively. If the I^2 value is less than 30%, a fixed-effect model is used. If the I^2 value is greater than 30%, a random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI = confidence interval (represented by the lines).

Additional file 7: Fig. S7. H-Y score pre- versus post-transplantation in the 'on' or 'off' states at the last follow-up after autologous cell treatment. Two studies are included. Random-effect model is used. The sizes of squares represent the weight that each study contributes. The diamond at the bottom represents the overall effect. CI = confidence interval (represented by the lines).

Additional file 8: Fig. S8. Funnel plots assessing potential publication bias on homogeneous cell transplantation in PD treatment. (a) UPDRS or UPDRSIII scores pre- versus post-transplantation in 'on' or 'off' state at the last follow-up. (b) UPDRS score pre- versus post-transplantation in the 'off' state at last follow-up. (c) UPDRSIII score pre- versus post-transplantation in the 'off' state at last follow-up. (d) UPDRSIII scores pre- versus post-transplantation in the 'off' states at the last follow-up with levodopa responders. (e) UPDRS scores pre- versus post-transplantation in the 'off' states after allogeneic cell treatment. (f) UPDRSIII scores pre- versus post-transplantation in the 'off' states at the last follow-ups after allogeneic cell treatment. Each dot represents a single study. The dashed vertical line represents the pooled effect size. The dashed diagonal lines represent 95% confidence limits around the pooled effect size for each standard error on the vertical axis, and are only provided in plots when fixed effect models were used.

Additional file 9: Table S1. Fetal mesencephalic tissue transplantation: characteristics of the studies and subjects.

Additional file 10: Table S2. Adrenal medulla transplantation: characteristics of the studies and subjects.

Acknowledgements

None.

Author contributions

FW, ZWS, DYP, and SL had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. JB and SL conceived and designed the study. FW, ZWS, DYP, and SL undertook the statistical analyses. FW, ZWS, and DYP made figures. All authors advised on statistical analyses and visualization. FW and ZWS wrote the first draft of the manuscript. All authors made critical revisions of the manuscript for important intellectual content. All authors have read and approved the final version of the manuscript.

Funding

This work was supported by National Natural Science Foundation of China (82171319) and Central Committee Healthcare Project (2020YB64).

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations**Ethics approval and consent to participate**

Not applicable.

Consent for Publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Neurology, Central Hospital of Dalian University of Technology, Dalian, China. ²Department of Clinical Pharmacy, Central Hospital of Dalian University of Technology, Dalian, China. ³School of Life Sciences, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK. ⁴Institute of Neurology, Sichuan Academy of Medical Sciences, Sichuan Provincial Hospital, Chengdu, China. ⁵Department of Neurology and Psychiatry, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Beijing 100038, China. ⁶Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China.

Received: 5 April 2023 Accepted: 30 August 2023

Published online: 07 September 2023

References

- Church FC. Treatment options for motor and non-motor symptoms of Parkinson's disease. *Biomolecules*. 2021;11(4):612.
- Harris JP, Burrell JC, Struzyna LA, Chen H, Serruya MD, Wolf JA, et al. Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease. *NPJ Parkinsons Dis*. 2020;6:4.
- Polgar S, Morris ME, Reilly S, Bilney B, Sanberg PR. Reconstructive neurosurgery for Parkinson's disease: a systematic review and preliminary meta-analysis. *Brain Res Bull*. 2003;60(1–2):1–24.
- Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. *N Engl J Med*. 2020;382(20):1926–32.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
- Sonntag KC, Song B, Lee N, Jung JH, Cha Y, Leblanc P, et al. Pluripotent stem cell-based therapy for Parkinson's disease: current status and future prospects. *Prog Neurobiol*. 2018;168:1–20.
- Lindvall O. Clinical translation of stem cell transplantation in Parkinson's disease. *J Intern Med*. 2016;279(1):30–40.
- Lindvall O, Björklund A. Cell therapeutics in Parkinson's disease. *Neurotherapeutics*. 2011;8(4):539–48.
- Yasuhara T, Kameda M, Sasaki T, Tajiri N, Date I. Cell therapy for Parkinson's disease. *Cell Transplant*. 2017;26(9):1551–9.
- Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program for intracerebral transplantations (CAPIT). *Mov Disord*. 1992;7(1):2–13.
- Higgins J, Green S. The Cochrane Collaboration. *Cochrane handbook for systematic reviews of interventions*. New York: Wiley; 2011.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–88.
- McRae C, Caspari J, Russell D, Ellgring H, Bezzant C, Greene P, et al. Video review of baseline performance on global ratings in a double-blind placebo surgery trial. *Mov Disord Clin Pract*. 2018;5(6):597–602.
- Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, et al. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. *J Nucl Med*. 2010;51(1):7–15.
- McRae C, Cherin E, Yamazaki TG, Diem G, Vo AH, Russell D, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. *Arch Gen Psychiatry*. 2004;61(4):412–20.
- Gordon PH, Yu Q, Qualls C, Winfield H, Dillon S, Greene PE, et al. Reaction time and movement time after embryonic cell implantation in Parkinson disease. *Arch Neurol*. 2004;61(6):858–61.
- Trott CT, Fahn S, Greene P, Dillon S, Winfield H, Winfield L, et al. Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study. *Neurology*. 2003;60(12):1938–43.
- McRae C, Cherin E, Diem G, Vo AH, Ellgring JH, Russell D, et al. Does personality change as a result of fetal tissue transplantation in the brain? *J Neurol*. 2003;250(3):282–6.
- Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. *Ann Neurol*. 2002;52(5):628–34.
- Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. *N Engl J Med*. 2001;344(10):710–9.
- Nakamura T, Dhawan V, Chaly T, Fukuda M, Ma Y, Breeze R, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. *Ann Neurol*. 2001;50(2):181–7.
- Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. *Mov Disord*. 2009;24(3):336–43.
- Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. *Ann Neurol*. 2003;54(3):403–14.
- Pogarell O, Koch W, Gildehaus FJ, Kupsch A, Lindvall O, Oertel WH, et al. Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. *Eur J Nucl Med Mol Imaging*. 2006;33(4):407–11.
- Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazareoids in Parkinson's disease. *Brain*. 2000;123(7):1380–90.
- Hagell P, Crabb L, Pogarell O, Schrag A, Widner H, Brooks DJ, et al. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. *Mov Disord*. 2000;15(2):224–9.
- Piccini P, Lindvall O, Björklund A, Brundin P, Hagell P, Ceravolo R, et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. *Ann Neurol*. 2000;48(5):689–95.
- Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehnrcrona S, et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. *Brain*. 1999;122(6):1121–32.
- Wenning GK, Odin P, Morrish P, Rehnrcrona S, Widner H, Brundin P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. *Ann Neurol*. 1997;42(1):95–107.
- Lindvall O, Sawle G, Widner H, Rothwell JC, Björklund A, Brooks D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. *Ann Neurol*. 1994;35(2):172–80.
- Sawle GV, Bloomfield PM, Björklund A, Brooks DJ, Brundin P, Leenders KL, et al. Transplantation of fetal dopamine neurons in Parkinson's

- disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. *Ann Neurol.* 1992;31(2):166–73.
32. Lindvall O, Widner H, Rehnström S, Brundin P, Odin P, Gustavii B, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. *Ann Neurol.* 1992;31(2):155–65.
 33. Lindvall O, Rehnström S, Brundin P, Gustavii B, Astedt B, Widner H, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. *Arch Neurol.* 1989;46(6):615–31.
 34. Lindvall O, Rehnström S, Gustavii B, Brundin P, Astedt B, Widner H, et al. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. *Lancet.* 1988;2(8626–8627):1483–4.
 35. Schumacher JM, Elias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. *Neurology.* 2000;54(5):1042–50.
 36. Fink JS, Schumacher JM, Elias SL, Palmer EP, Saint-Hilaire M, Shannon K, et al. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. *Cell Transplant.* 2000;9(2):273–8.
 37. Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. *Nat Med.* 1997;3(3):350–3.
 38. Jacques DB, Kopyov OV, Eagle KS, Carter T, Lieberman A. Outcomes and complications of fetal tissue transplantation in Parkinson's disease. *Stereotact Funct Neurosurg.* 1999;72(2–4):219–24.
 39. Kopyov OV, Jacques DS, Lieberman A, Duma CM, Rogers RL. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. *Exp Neurol.* 1997;146(2):536–45.
 40. Kopyov OV, Jacques D, Lieberman A, Duma CM, Rogers RL. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's disease. *Cell Transplant.* 1996;5(2):327–37.
 41. Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I Clinical approach. *Brain.* 1996;119(1):41–50.
 42. Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. *Ann Neurol.* 1995;38(4):580–8.
 43. Peschanski M, Defer G, N'Guyen JP, Ricolfi F, Monfort JC, Remy P, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. *Brain.* 1994;117(3):487–99.
 44. Sass KJ, Buchanan CP, Westerveld M, Marek KL, Farhi A, Robbins RJ, et al. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. *Arch Neurol.* 1995;52(7):680–6.
 45. Price LH, Spencer DD, Marek KL, Robbins RJ, Leranth C, Farhi A, et al. Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. *Biol Psychiatry.* 1995;38(8):498–505.
 46. Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. *N Engl J Med.* 1992;327(22):1541–8.
 47. Henderson B, Good PA, Hitchcock ER, Clough CG, Hughes RC, Kenny BG. Visual evoked cortical responses and electroretinograms following implantation of human fetal mesencephalon to the right caudate nucleus in Parkinson's disease. *J Neurol Sci.* 1992;107(2):183–90.
 48. Henderson BT, Clough CG, Hughes RC, Hitchcock ER, Kenny BG. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. *Arch Neurol.* 1991;48(8):822–7.
 49. Hitchcock ER, Kenny BG, Clough CG, Hughes RC, Henderson BT, Detta A. Stereotactic implantation of foetal mesencephalon (STIM): the UK experience. *Prog Brain Res.* 1990;82:723–8.
 50. Hitchcock ER, Clough C, Hughes R, Kenny B. Embryos and Parkinson's disease. *Lancet.* 1988;1(8597):1274.
 51. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. *Arch Neurol.* 1999;56(2):179–87.
 52. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. *Ann Neurol.* 1995;38(3):379–88.
 53. Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. *J Comp Neurol.* 1996;370(2):203–30.
 54. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. *N Engl J Med.* 1995;332(17):1118–24.
 55. Barker RA. Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. *Nat Med.* 2019;25(7):1045–53.
 56. Li JY, Englund E, Widner H, Rehnström S, Björklund A, Lindvall O, et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. *Mov Disord.* 2010;25(8):1091–6.
 57. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. *Nat Med.* 2008;14(5):504–6.
 58. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. *Mov Disord.* 2008;23(16):2303–6.
 59. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. *Nat Med.* 2008;14(5):501–3.
 60. Mendez I, Viñuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. *Nat Med.* 2008;14(5):507–9.
 61. Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc'h C, et al. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. *Mov Disord.* 2003;18(8):928–32.
 62. Wu C, Liu Y, Wang J, Yang Y, Jiang Y. Intracerebral transplantation of nerve cells and genetically modified cells for disorders of central nervous system, a basic and clinical study. *Zhonghua Yi Xue Za Zhi.* 2002;82(7):440–4.
 63. Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. *J Neurosurg.* 2000;92(5):863–9.
 64. Ross BD, Hoang TQ, Blüml S, Dubowitz D, Kopyov OV, Jacques DB, et al. In vivo magnetic resonance spectroscopy of human fetal neural transplants. *NMR Biomed.* 1999;12(4):221–36.
 65. Piccini P, Brooks DJ, Björklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. *Nat Neurosci.* 1999;2(12):1137–40.
 66. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. *Mov Disord.* 1998;13(3):383–93.
 67. Mamelak AN, Eggerding FA, Oh DS, Wilson E, Davis RL, Spitzer R, et al. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease. *J Neurosurg.* 1998;89(4):592–8.
 68. Levivier M, Dethy S, Rodesch F, Peschanski M, Vandesteene A, David P, et al. Intracerebral transplantation of fetal ventral mesencephalon for patients with advanced Parkinson's disease. Methodology and 6-month to 1-year follow-up in 3 patients. *Stereotact Funct Neurosurg.* 1997;69(2):99–111.
 69. López-Lozano JJ, Bravo G, Brera B, Millán I, Dargallo J, Salmeán J, et al. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. *Clinica Puerta de Hierro Neural Transplantation Group.* *J Neurosurg.* 1997;86(6):931–42.
 70. Baker KK, Ramig LO, Johnson AB, Freed CR. Preliminary voice and speech analysis following fetal dopamine transplants in 5 individuals with Parkinson disease. *J Speech Lang Hear Res.* 1997;40(3):615–26.
 71. Folkerth RD, Durso R. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. *Neurology.* 1996;46(5):1219–25.
 72. Ząbek M, Mazurowski W, Dymecki J, Stelmachów J, Zawada E. A long term follow-up of fetal dopaminergic neurons transplantation into the brain of three parkinsonian patients. *Restor Neurol Neurosci.* 1994;6(2):97–106.

73. Markham CM, Rand RW, Jacques DB, Diamond SG, Kopyov OV, Snow B. Transplantation of fetal mesencephalic tissue in Parkinson's patients. *Stereotact Funct Neurosurg.* 1994;62(1-4):134-40.
74. Molina H, Quiñones R, Ortega I, Alvarez L, Muñoz J, Gonzalez C, et al. Computer assisted CT-guided stereotactic transplantation of foetal ventral mesencephalon to the caudate nucleus and putamen in Parkinson's disease. *Acta Neurochir Suppl (Wien).* 1993;58:17-9.
75. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. *N Engl J Med.* 1992;327(22):1549-55.
76. Lindvall O, Brundin P, Widner H, Rehnström S, Gustavii B, Frackowiak R, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. *Science.* 1990;247(4942):574-7.
77. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. *Arch Neurol.* 1990;47(5):505-12.
78. Madrazo I, León V, Torres C, Aguilera MC, Varela G, Alvarez F, et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. *N Engl J Med.* 1988;318(1):51.
79. Porena M, Parziani S, Costantini E, Vespasiani G, Micali F. Autologous adrenal medullary transplant in Parkinson's disease: critical review of our results in 13 patients. *NeuroUrol Urodyn.* 1996;15(3):195-201.
80. Sydow O, Hansson P, Young D, Meyerson B, Backlund EO, Ebendal T, et al. Long-term beneficial effects of adrenal medullary autografts supported by nerve growth factor in Parkinson's disease. *Eur J Neurol.* 1995;2(5):445-54.
81. Diamond SG, Markham CH, Rand RW, Becker DP, Treziokas LJ. Four-year follow-up of adrenal-to-brain transplants in Parkinson's disease. *Arch Neurol.* 1994;51(6):559-63.
82. Goetz CG, Stebbins GT 3rd, Klawans HL, Koller WC, Grossman RG, Bakay RA, et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. *Neurology.* 1991;41(11):1719-22.
83. Jimenez F, Velasco F, Velasco M, Velasco AL. Long-term effects of medical and surgical treatments on Parkinson's disease. *Stereotact Funct Neurosurg.* 1994;62(1-4):85-9.
84. Madrazo I, Franco-Bourland R, Aguilera M, Ostrosky-Solis F, Madrazo M, Cuevas C, et al. Autologous adrenal medullary, fetal mesencephalic, and fetal adrenal brain transplantation in Parkinson's disease: a long-term postoperative follow-up. *J Neural Transplant Plast.* 1991;2(3-4):157-64.
85. Velasco F, Velasco M, Rodríguez Cuevas H, Jurado J, Olvera J, Jiménez F. Autologous adrenal medullary transplants in advanced Parkinson's disease with particular attention to the selective improvement in symptoms. *Stereotact Funct Neurosurg.* 1991;57(4):195-212.
86. Olson L, Backlund EO, Ebendal T, Freedman R, Hamberger B, Hansson P, et al. Intraputaminial infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial. *Arch Neurol.* 1991;48(4):373-81.
87. Kordower JH, Cochran E, Penn RD, Goetz CG. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease. *Ann Neurol.* 1991;29(4):405-12.
88. López-Lozano JJ, Bravo G, Abascal J. Grafting of perfused adrenal medullary tissue into the caudate nucleus of patients with Parkinson's disease. *Clinica Puerta de Hierro Neural Transplantation Group. J Neurosurg.* 1991;75(2):234-43.
89. Skinner EC, Boyd SD, Apuzzo ML. Technique of left adrenalectomy for autotransplantation to the caudate nucleus in Parkinson's disease. *J Urol.* 1990;144(4):838-41.
90. Goetz CG, Olanow CW, Koller WC, Penn RD, Cahill D, Morantz R, et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. *N Engl J Med.* 1989;320(6):337-41.
91. Penn RD, Goetz CG, Tanner CM, Klawans HL, Shannon KM, Comella CL, et al. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. *Neurosurgery.* 1988;22(1):999-1004.
92. Lindvall O, Backlund EO, Farde L, Sedvall G, Freedman R, Hoffer B, et al. Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen. *Ann Neurol.* 1987;22(4):457-68.
93. Madrazo I, Drucker-Colín R, Díaz V, Martínez-Mata J, Torres C, Becerril JJ. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. *N Engl J Med.* 1987;316(14):831-4.
94. Backlund EO, Granberg PO, Hamberger B, Knutsson E, Mårtensson A, Sedvall G, et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. *J Neurosurg.* 1985;62(2):169-73.
95. Mínguez-Castellanos A, Escamilla-Sevilla F, Hotton GR, Toledo-Aral JJ, Ortega-Moreno A, Méndez-Ferrer S, et al. Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. *J Neurol Neurosurg Psychiatry.* 2007;78(8):825-31.
96. Arjona V, Mínguez-Castellanos A, Montoro RJ, Ortega A, Escamilla F, Toledo-Aral JJ, et al. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. *Neurosurgery.* 2003;53(2):321-30.
97. Nakao N, Kakishita K, Uematsu Y, Yoshimasu T, Bessho T, Nakai K, et al. Enhancement of the response to levodopa therapy after intrastriatal transplantation of autologous sympathetic neurons in patients with Parkinson disease. *J Neurosurg.* 2001;95(2):275-84.
98. Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease. *Exp Neurol.* 2004;188(1):65-73.
99. Itakura T, Uematsu Y, Nakao N, Nakai E, Nakai K. Transplantation of autologous sympathetic ganglion into the brain with Parkinson's disease. Long-term follow-up of 35 cases. *Stereotact Funct Neurosurg.* 1997;69(2):112-5.
100. Itakura T, Nakai M, Nakao N, Ooiwa Y, Uematsu Y, Komai N. Transplantation of autologous cervical sympathetic ganglion into the brain with Parkinson's disease: experimental and clinical studies. *Cell Transplant.* 1994;3(Suppl 1):43-5.
101. Sustens M, Haq I, Martínez-Cerrato J, Dos-Anjos S, Bertram K, Correa D. Sustained clinical improvement of Parkinson's disease in two patients with facially-transplanted adipose-derived stromal vascular fraction cells. *J Clin Neurosci.* 2020;81:47-51.
102. Schiess M, Suessun J, Doursout MF, Adams C, Green C, Saltarelli JG, et al. Allogeneic bone marrow-derived mesenchymal stem cell safety in idiopathic Parkinson's disease. *Mov Disord.* 2021;36(8):1825-34.
103. Venkataramana NK, Pal R, Rao SA, Naik AL, Jan M, Nair R, et al. Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson's disease: a pilot clinical study. *Stem Cells Int.* 2012;2012:931902.
104. Boika A, Aleinikava N, Chyzyk V, Zafanskaya M, Nizheharodava D, Ponomarev V. Mesenchymal stem cells in Parkinson's disease: motor and nonmotor symptoms in the early posttransplant period. *Surg Neurol Int.* 2020;11:380.
105. Storch A, Csoti I, Eggert K, Henriksen T, Plate A, Lorrain M, et al. Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. *Mov Disord.* 2012;27(12):1552-5.
106. Brazzini A, Cantella R, De la Cruz A, Yupanqui J, León C, Jorquiera T, et al. Intraarterial autologous implantation of adult stem cells for patients with Parkinson disease. *J Vasc Interv Radiol.* 2010;21(4):443-51.
107. Madrazo I, Kopyov O, Ávila-Rodríguez MA, Ostrosky F, Carrasco H, Kopyov A, et al. Transplantation of human neural progenitor cells (NPC) into putamina of parkinsonian patients: a case series study, safety and efficacy four years after surgery. *Cell Transplant.* 2019;28(3):269-85.
108. Lige L, Zengmin T. Transplantation of neural precursor cells in the treatment of parkinson disease: an efficacy and safety analysis. *Turk Neurosurg.* 2016;26(3):378-83.
109. Sinelnik A, Sych N, Klunyk M, Demchuk M, Ivankova O. Non-motor symptoms in Parkinson's disease and efficacy of treatment in a complex therapy using fetal stem cells. *J Stem Cell Res Ther.* 2015;5(300):2.
110. Yin F, Tian ZM, Liu S, Zhao QJ, Wang RM, Shen L, et al. Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease. *CNS Neurosci Ther.* 2012;18(12):1012-20.
111. Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, et al. Intrastriatal transplantation of microcarrier-bound human retinal

- pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurol.* 2011;10(6):509–19.
112. Stover NP, Bakay RAE, Subramanian T, Raiser CD, Cornfeldt ML, Schweikert AW, et al. Intrastratial implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. *Arch Neurol.* 2005;62(12):1833–7.
 113. Bakay RA, Raiser CD, Stover NP, Subramanian T, Cornfeldt ML, Schweikert AW, et al. Implantation of Spheramine in advanced Parkinson's disease (PD). *Front Biosci.* 2004;9:592–602.
 114. Venkataramana NK, Kumar SK, Balaraju S, Radhakrishnan RC, Bansal A, Dixit A, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. *Transl Res.* 2010;155(2):62–70.
 115. Snow B, Mulroy E, Bok A, Simpson M, Smith A, Taylor K, et al. A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL[®] [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease. *Parkinsonism Relat Disord.* 2019;61:88–93.
 116. Mulroy E, Snow B, Bok A, Simpson M, Smith A, Taylor KM, et al. A long-term follow-up of safety and clinical efficacy of NTCELL[®] [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease. *Parkinsonism Relat Disord.* 2021;82:128–32.
 117. Farag ES, Vinters HV, Bronstein J. Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease. *Neurology.* 2009;73(14):1095–102.
 118. Peterson DI, Price ML, Small CS. Autopsy findings in a patient who had an adrenal-to-brain transplant for Parkinson's disease. *Neurology.* 1989;39(1):235–8.
 119. Toledo-Aral JJ, Méndez-Ferrer S, Pardal R, Echevarría M, López-Barneo J. Trophic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body-grafted parkinsonian rats. *J Neurosci.* 2003;23(1):141–8.
 120. Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. *Science.* 1979;204(4393):643–7.
 121. Björklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. *Brain Res.* 1979;177(3):555–60.
 122. Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. *Cell Rep.* 2014;7(6):1755–61.
 123. Li W, Englund E, Widner H, Mattsson B, van Westen D, Lätt J, et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. *Proc Natl Acad Sci U S A.* 2016;113(23):6544–9.
 124. Mendez I, Sanchez-Pernaute R, Cooper O, Viñuela A, Ferrari D, Björklund L, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. *Brain.* 2005;128(7):1498–510.
 125. Wei M, Li S, Yang Z, Cheng C, Li T, Le W. Tetrahedral DNA nanostructures functionalized by multivalent microRNA132 antisense oligonucleotides promote the differentiation of mouse embryonic stem cells into dopaminergic neurons. *Nanomedicine.* 2021;34:102375.
 126. Wei M, Li S, Yang Z, Zheng W, Le W. Gold nanoparticles enhance the differentiation of embryonic stem cells into dopaminergic neurons via mTOR/p70S6K pathway. *Nanomedicine (Lond).* 2017;12(11):1305–17.
 127. Yang D, Li T, Xu M, Gao F, Yang J, Yang Z, et al. Graphene oxide promotes the differentiation of mouse embryonic stem cells to dopamine neurons. *Nanomedicine (Lond).* 2014;9(16):2445–55.
 128. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. *Mov Disord.* 2003;18(7):738–50.
 129. Piccini P, Pavese N, Hagell P, Reimer J, Björklund A, Oertel WH, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. *Brain.* 2005;128(12):2977–86.
 130. Freed CR, Breeze RE, Fahn S, Eidelberg D. Preoperative response to levodopa is the best predictor of transplant outcome. *Ann Neurol.* 2004;55(6):896–7.
 131. Li S, Oh BC, Chu C, Arnold A, Jablonska A, Furtmüller GJ, et al. Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts. *Brain.* 2019;142(11):3456–72.
 132. Lane EL, Vercammen L, Cenci MA, Brundin P. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. *Exp Neurol.* 2009;219(1):355–8.
 133. Carlsson T, Winkler C, Lundblad M, Cenci MA, Björklund A, Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. *Neurobiol Dis.* 2006;21(3):657–68.
 134. Maries E, Kordower JH, Chu Y, Collier TJ, Sortwell CE, Olanow E, et al. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. *Neurobiol Dis.* 2006;21(1):165–80.
 135. Carlsson T, Carta M, Winkler C, Björklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. *J Neurosci.* 2007;27(30):8011–22.
 136. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehnacrona S, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. *Sci Transl Med.* 2010;2(38):38ra46.
 137. Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, et al. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. *Mov Disord.* 2011;26(11):1997–2003.
 138. Politis M, Wu K, Loane C, Kiferle L, Mollooy S, Brooks DJ, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. *Neurobiol Dis.* 2010;40(1):216–21.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

